NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of AutoNation Inc. (NYSE: AN), Hanesbrands Inc. (NYSE: HBI), Northrop Grumman Corporation (NYSE: NOC), Sunstone Hotel Investors...
Patheon (Booth 1232) has named William E. Weiser, Ph.D. to the role of group director, Pharmaceutical Development Services (PDS), Analytical Development at the company's Kit Creek laboratory in Research Triangle Park, NC. Also, Anthony Qu, Ph.D. has been named group director of the PDS operation in Cincinnati, OH. "We are so pleased that we have been able to add these two individuals to our organization,"...
In case you failed to run a Google search this week, you may not have realized that on Tuesday Nov. 10, Sesame Street turns 40 . You gotta admit, the show doesn't look a day over five--and that's without Botox. If you've forgotten how to get to Sesame Street , we have a few reminders--and ear worms -- appropriately tailored for the biopharma industry--hey, it's our version of personalized medicine...
Biovail (NYSE: BVF) closed yesterday at $13.25. So far the stock has hit a 52-week low of $7.35 and 52-week high of $15.50. Biovail stock has been showing support around 13.06 and resistance in the 13.58 range. Technical indicators for the stock are Bearish and S&P gives BVF a positive 4 STAR (out of 5) buy rating. BVF appears on the Investors Observer Hedged Dividend Income list. For a hedged...
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE/TSX: BVF) today announced financial results for the three-month and nine-month periods ended September 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these statements are based on the Company’s current views, and actual outcomes are not certain. For more information, see the note...
Biovail (NYSE: BVF) closed yesterday at $13.34. So far the stock has hit a 52-week low of $7.35 and 52-week high of $15.50. Biovail stock has been showing support around 12.73 and resistance in the 13.77 range. Technical indicators for the stock are Bearish and S&P gives BVF a positive 4 STAR (out of 5) buy rating. BVF appears on the Investors Observer Hedged Dividend Income list. For a hedged...
Biovail (NYSE: BVF) closed yesterday at $13.39. So far the stock has hit a 52-week low of $7.35 and 52-week high of $15.50. Biovail stock has been showing support around 13.09 and resistance in the 13.77 range. Technical indicators for the stock are Bearish and S&P gives BVF a positive 4 STAR (out of 5) buy rating. BVF appears on the Investors Observer Hedged Dividend Income list. For a hedged...
LONDON (MARKET WIRE) Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities. Today we began research on Allstate Corp. (NYSE: ALL), Northrop Grumman Corporation (NYSE: NOC), Radian Group Inc. (NYSE: RDN), Biovail Corporation (NYSE: BVF), Titanium Metals Corp. (NYSE:...
NORWALK, CT (MARKET WIRE) Elsevier Business Intelligence and Windhover Conferences have announced their complete Top 10 Projects to Watch for the upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. This year's list will offer a Top 10 in each of four therapeutic areas: cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune. Past Windhover top 10 candidates...
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that it will host a conference call and webcast on Thursday, November 5, 2009 at 8:30a.m. for Company executives to discuss third-quarter 2009 financial and operational results. Following the discussion, Biovail executives will address inquiries from investment analysts. A live webcast of this call will be available...
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail...
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE/TSX: BVF) today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to...
Biovail (NYSE: BVF) closed yesterday at $15.43. So far the stock has hit a 52-week low of $6.65 and 52-week high of $15.50. Biovail stock has been showing support around 14.61 and resistance in the 15.91 range. Technical indicators for the stock are Bullish and S&P gives BVF a positive 4 STAR (out of 5) buy rating. BVF appears on the Investors Observer Hedged Dividend Income list. For a hedged...
Biovail Laboratories has signed an agreement with Santhera Pharmaceuticals, entitling Biovail to the US and Canadian rights to develop and commercialize fipamezole (also known as JP-1730), for the treatment of levodopa-induced dyskinesia in Parkinson's disease. The agreement involves an upfront payment of US$8 million from
Videos